Insulin discovery: A pivotal point in medical history.
Level 5 - mechanism / opinion, no new human data
Narrative historical review with no original empirical data or systematic synthesis.
PubMed 34838778 · doi:10.1016/j.metabol.2021.154941
What was done
This paper provides a historical narrative review tracing the milestones following the 1921 discovery of insulin by the Toronto research team. It outlines biochemical achievements including hormone purification, amino acid sequencing, recombinant DNA synthesis, and structural modifications altering pharmacokinetic and pharmacodynamic profiles, as well as emerging delivery technologies.
What was found
The abstract reports no numerical or quantitative findings. It describes qualitative historical milestones and technological progression, noting that formulation improvements have aimed to reproduce physiological diurnal insulin fluctuations and that once-weekly and glucose-responsive insulins are entering clinical development.
Why it matters
The paper contextualizes one hundred years of diabetes therapeutics, highlighting how biotechnology and delivery engineering have continually advanced to improve the safety, efficacy, and quality of life for individuals with diabetes.
Limits
As a narrative historical review, it includes no original clinical or empirical data, quantitative metrics, or systematic search methodology. Specific trial outcomes and safety profiles for emerging formulations are not reported in the abstract.
Cited by
- supports Insulin was the first peptide isolated and used in medicine in 1921.